{"id":3163,"date":"2026-04-21T15:55:53","date_gmt":"2026-04-21T13:55:53","guid":{"rendered":"https:\/\/fungki.com\/waarom-de-vs-inzet-op-psilocybine-opzoek\/"},"modified":"2026-05-30T19:31:15","modified_gmt":"2026-05-30T17:31:15","slug":"why-the-u-s-is-investing-in-psilocybin-research","status":"publish","type":"post","link":"https:\/\/fungki.com\/en\/why-the-u-s-is-investing-in-psilocybin-research\/","title":{"rendered":"Why the U.S. is investing in psilocybin research"},"content":{"rendered":"

Last weekend, the United States signed off on a decision to accelerate research into psychedelics. That moment is bigger than it seems. Not because something entirely new is emerging, but because what was already underway is now being formally recognized. Psychedelics are shifting from the fringes to a serious medical direction.<\/strong><\/p>\n

What\u2019s actually changing<\/h3>\n

The United States isn\u2019t choosing legalization. It\u2019s choosing acceleration. Research into substances like psilocybin, MDMA, and ibogaine is being actively encouraged. Access to experimental treatments is being expanded. And agencies like the Food and Drug Administration are being directed to evaluate these therapies more quickly and with greater focus. The underlying message is clear: psychedelic research is no longer a niche – it belongs in the medical domain.<\/p>\n

Why this is happening now<\/h3>\n

This decision didn\u2019t come out of nowhere. It\u2019s the result of three developments converging.<\/p>\n

    \n
  1. The first results are too strong to ignore
    \nClinical studies show that psychedelics can, in some cases, have rapid effects on depression, trauma, and addiction – sometimes after just one or a few sessions.<\/li>\n
  2. Current solutions fall short
    \nFor a large group of people, existing treatments simply aren\u2019t effective enough. That creates both space – and urgency – for new approaches.<\/li>\n
  3. Practice has moved ahead of policy
    \nMore and more people are already seeking out these treatments, often outside the traditional system. That puts pressure on regulation to catch up.<\/li>\n<\/ol>\n

    Together, these three lines lead to one clear conclusion:
    the system can no longer ignore this.<\/strong><\/p><\/blockquote>\n

    But this is not a free pass<\/h3>\n

    The nuance matters. This policy does not mean psychedelics are the solution. It means they need to be taken seriously – and studied properly, under the right conditions. Because:<\/p>\n